NEW HAVEN, Conn. - Biohaven Ltd. (NYSE: BHVN), a company engaged in the development of treatments in areas such as immunology and neuroscience, announced the commencement of a public offering of $200 million of its common shares. The offering includes an additional option for the underwriter to purchase up to $30 million of shares, depending on market conditions.
The proceeds from the sale, which is being managed by J.P. Morgan Securities LLC, are intended for general corporate purposes. While the offering is currently underway, its completion is not guaranteed and is subject to market conditions.
The shares are being offered via a prospectus supplement and an accompanying prospectus. Potential investors are advised to read these documents, which are available through J.P. Morgan Securities LLC, as well as other filings made by Biohaven with the Securities and Exchange Commission.
This announcement contains forward-looking statements, and investors are cautioned that these are not guarantees of future performance. Factors such as market conditions and Biohaven's ability to complete the offering could affect the outcome. The company has made it clear that it does not intend to update any forward-looking statements unless required by law.
The information in this article is based on a press release statement from Biohaven Ltd.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.